Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV, Multicenter, Open Label, Randomized Study of Rebif 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis

Trial Profile

Phase IV, Multicenter, Open Label, Randomized Study of Rebif 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Interferon beta-1a (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms REGARD
  • Sponsors EMD Serono
  • Most Recent Events

    • 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.
    • 27 Jun 2017 Results (n=917) assessing predictive value of modified Rio score using patient data from REFLEX(ION), REGARD, SPECTRIMS and PRISMS trials presented at the 3rd Congress of the European Academy of Neurology
    • 11 Oct 2007 Results reported at ECTRIMS 2007 (1087283 and 1087295)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top